University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Arts
  • School of Historical and Philosophical Studies
  • School of Historical and Philosophical Studies - Research Publications
  • View Item
  • Minerva Access
  • Arts
  • School of Historical and Philosophical Studies
  • School of Historical and Philosophical Studies - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    The road to commercialization in Africa: lessons from developing the sickle-cell drug Niprisan

    Thumbnail
    Download
    published version (232.9Kb)

    Citations
    Scopus
    Web of Science
    Altmetric
    6
    4
    Author
    Perampaladas, K; Masum, H; Kapoor, A; Shah, R; Daar, AS; Singer, PA
    Date
    2010-12-01
    Source Title
    BMC International Health and Human Rights
    Publisher
    BIOMED CENTRAL LTD
    University of Melbourne Author/s
    Singer, Peter
    Affiliation
    School of Historical and Philosophical Studies
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Perampaladas, K., Masum, H., Kapoor, A., Shah, R., Daar, A. S. & Singer, P. A. (2010). The road to commercialization in Africa: lessons from developing the sickle-cell drug Niprisan. BMC INTERNATIONAL HEALTH AND HUMAN RIGHTS, 10 (SUPPL. 1), https://doi.org/10.1186/1472-698X-10-S1-S11.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/256907
    DOI
    10.1186/1472-698X-10-S1-S11
    Abstract
    BACKGROUND: Developing novel drugs from traditional medicinal knowledge can serve as a means to improve public health. Yet countries in sub-Saharan Africa face barriers in translating traditional medicinal knowledge into commercially viable health products. Barriers in moving along the road towards making a new drug available include insufficient manufacturing capacity; knowledge sharing between scientists and medical healers; regulatory hurdles; quality control issues; pricing and distribution; and lack of financing. The case study method was used to illustrate efforts to overcome these barriers during the development in Nigeria of Niprisan - a novel drug for the treatment of sickle cell anemia, a chronic blood disorder with few effective therapies. DISCUSSION: Building on the knowledge of a traditional medicine practitioner, Nigeria's National Institute for Pharmaceutical Research and Development (NIPRD) developed the traditional herbal medicine Niprisan. The commercialization of Niprisan reached a number of commercial milestones, including regulatory approval in Nigeria; securing US-based commercial partner XeChem; demonstrating clinical efficacy and safety; being awarded orphan drug status by the US Food and Drug Administration; and striking important relationships with domestic and international groups. Despite these successes, however, XeChem did not achieve mainstream success for Niprisan in Nigeria or in the United States. A number of reasons, including inconsistent funding and manufacturing and management challenges, have been put forth to explain Niprisan's commercial demise. As of this writing, NIPRD is considering options for another commercial partner to take the drug forward. SUMMARY: Evidence from the Niprisan experience suggests that establishing benefit-sharing agreements, fostering partnerships with established research institutions, improving standardization and quality control, ensuring financial and managerial due diligence, and recruiting entrepreneurial leaders capable of holding dual scientific and business responsibilities should be incorporated into future drug development initiatives based on traditional medicines. Country-level supporting policies and conditions are also important. With more experience and support, and an improved environment for innovation, developing new drugs from traditional medicines may be an attractive approach to addressing diseases in sub-Saharan Africa and other regions.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [53102]
    • School of Historical and Philosophical Studies - Research Publications [1520]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors